---
id: 083
title: Pneumonia Empiric Therapy (CAP vs HAP/VAP)
category: clinical_syndromes
subcategory: pneumonia
tags: [CAP, HAP, VAP, empiric-therapy, MRSA, Pseudomonas]
difficulty: medium
---

## Question

What is empiric therapy for CAP vs HAP/VAP? Use the **"CAP = β-lactam + Macro vs HAP/VAP = Double Pseudomonas + MRSA"** mnemonic.

## Answer

### **Community-Acquired Pneumonia (CAP):**

**Outpatient (previously healthy):**
- **Amoxicillin 1g TID** OR
- **Doxycycline 100mg BID** OR
- **Macrolide** (azithromycin, clarithromycin) if low resistance

**Outpatient (comorbidities):**
- **Amoxicillin-clavulanate + macrolide** OR
- **Respiratory fluoroquinolone** (levofloxacin, moxifloxacin)

**Inpatient (non-ICU):**
- **β-lactam + macrolide:**
  - Ceftriaxone 1-2g daily + azithromycin 500mg daily
  - OR ampicillin-sulbactam + azithromycin

- **OR Respiratory fluoroquinolone** monotherapy:
  - Levofloxacin 750mg daily or moxifloxacin 400mg daily

**Inpatient (ICU):**
- **β-lactam + azithromycin** OR **β-lactam + respiratory fluoroquinolone:**
  - Ceftriaxone 2g daily + azithromycin 500mg daily
  - OR ceftriaxone + levofloxacin 750mg daily

**Add MRSA coverage if:**
- Prior MRSA infection
- Purulent sputum + MRSA colonization
- Influenza/viral pneumonia superinfection
- **MRSA coverage:** Vancomycin or linezolid

### **Hospital-Acquired Pneumonia (HAP) / Ventilator-Associated Pneumonia (VAP):**

**Standard HAP/VAP (no risk factors):**
- **Anti-pseudomonal β-lactam:**
  - Piperacillin-tazobactam 4.5g q6h OR
  - Cefepime 2g q8h OR
  - Meropenem 1g q8h

**HAP/VAP with MRSA risk factors:**
- **Anti-pseudomonal β-lactam** PLUS
- **MRSA coverage** (vancomycin or linezolid)

**HAP/VAP with MDR/high mortality risk:**
- **Double Pseudomonas coverage** (β-lactam + aminoglycoside or fluoroquinolone) PLUS
- **MRSA coverage**

**Example regimen:**
- Meropenem 1g q8h + tobramycin (or levofloxacin) + vancomycin

## Key Points

### **CAP Pathogen Coverage:**

| Pathogen | Covered By |
|----------|------------|
| ***S. pneumoniae*** | β-lactam |
| **Atypicals** (*Mycoplasma*, *Chlamydophila*, *Legionella*) | **Macrolide or fluoroquinolone** |
| ***H. influenzae*** | β-lactam |
| **Viruses** (influenza) | Consider oseltamivir if flu season |

**Key:** **Atypical coverage** essential (macrolide or fluoroquinolone)

### **HAP/VAP Pathogen Coverage:**

| Pathogen | Covered By |
|----------|------------|
| ***Pseudomonas aeruginosa*** | Anti-pseudomonal β-lactam (pip-tazo, cefepime, meropenem) |
| **MRSA** | Vancomycin or linezolid |
| **MDR Gram-negatives** | Carbapenems, double coverage if high risk |

### **MRSA Risk Factors (HAP/VAP):**
- Prior IV antibiotics within 90 days
- Prior MRSA colonization/infection
- Hospitalization in unit with high MRSA prevalence (>20%)

### **Duration:**
- **CAP:** 5-7 days (afebrile × 48-72 hrs + clinical stability)
- **HAP/VAP:** 7 days (can extend to 8-14 days if *Pseudomonas*, slow response, immunocompromised)

### **Clinical Pearls:**
- **CAP:** β-lactam + atypical coverage (macrolide or fluoroquinolone)
- **HAP/VAP:** Anti-pseudomonal β-lactam ± MRSA coverage
- **ICU CAP:** Always cover atypicals (azithromycin or fluoroquinolone)
- **Double Pseudomonas coverage** only if high risk (prior MDR, high mortality risk)
- De-escalate based on cultures + clinical response

## Sources

- [IDSA/ATS: CAP Guidelines 2019]
- [IDSA/ATS: HAP/VAP Guidelines 2016]

## Media

N/A
